Biotech fundraising in the UK is a different discipline. Rounds are larger, timelines are longer and the investor pool is specialised. Generalist VCs rarely operate here — the capital comes from biotech-dedicated funds, venture philanthropy and pharma corporate arms. Success hinges on scientific milestones, regulatory paths and the quality of your scientific advisory network.
A venture capital firm is a professional fund that invests pooled capital into high-growth startups in exchange for equity. Unlike angels investing their own money, VCs deploy capital on behalf of LPs — institutional investors, family offices and corporates. That shapes how they make decisions, the cheque sizes they write and the returns they expect.
UK biotech VC cheques typically range from £1m to £15m at seed and Series A, with rounds frequently north of £20m at Series B. Diligence runs eight to sixteen weeks with deep scientific validation, IP review and regulatory pathway assessment. Expect milestone-based tranche structures, board seats and active engagement on preclinical strategy. Many rounds combine equity with grants from Innovate UK or Wellcome.
Not every VC is the right VC for Biotechnology. When building a shortlist, compare them on:
Relevance beats reach. A sector-aligned VC will move faster, ask sharper questions and bring more than capital.
UK biotech has held strong investor interest despite broader capital pullback, driven by NHS-linked research output, Oxford-Cambridge cluster dynamics and strong government support. But the capital concentrates in dedicated biotech funds — founders who chase generalist VCs burn time.
Fit starts before the first meeting. Check each VC's recent investments, whether they led or followed and how portfolio founders describe the partnership post-close. Warm intros still matter — but the best ones come from shared context, not generic requests. A tight list of ten aligned VCs will outperform scattered outreach to fifty every time, especially in a tougher funding environment.
The right biotech VC will back your science through multiple milestones, structure capital that matches your development timeline and bring the pharma relationships that often matter more than valuation.
SFC Capital (formerly Startup Funding Club) is a leading early-stage investment firm providing capital and support to British startups.
By combining our Angel Network and Seed Funds, we have created a unique model that allows investors to get exposure to SEIS- and EIS-qualifying businesses, either directly or through a diversified portfolio curated and managed by our expert team.
SFC’s Angel House was formed to extend our impact as leaders of the UK's seed funding ecosystem. Over hundreds of deals, our network of angel investors has catalysed some of Britain's most exciting entrepreneurs and startups. The Angel House gives investor members access to SFC's winning fund portfolio.
Green Angel Ventures is the UK’s largest network of specialist investors fighting climate change – more than 350 members have joined. Together, we invest exclusively in the startup companies with the best technology and innovative processes to help tackle the climate crisis. In 2023, we were named Early Stage Investor of the Year at the Green Business Awards.
The telos of UpRoot Capital is to build a portfolio of early stage companies that are leveraging technology to support their clients deal with escalating pest, invasive species and biological risks across terrestrial and aquatic environments in our new climate reality.
Kelvin Capital was founded in 2009 and has since raised a total of over £113 million into 33 portfolio companies.
We invest venture capital in revenue generating growth companies which have the potential to deliver significant return to our investors.
We also invest in companies that require capital to grow their business.
For the right company with the right team, Kelvin Capital provides the investment and the support needed to deliver the true potential of their business.
